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RÉSUMÉ 
 
Dépistage précoce du diabète gestationnel 
 
par 
Masoud Mahdavian 
Programmes de sciences cliniques 
Mémoire présenté à la Faculté de médecine et des sciences de la santé en vue de l’obtention du 
diplôme de maitre ès sciences (M.Sc.) en sciences cliniques, Faculté de médecine et des sciences 
de la santé, Université de Sherbrooke, Sherbrooke, Québec, Canada, J1H 5N4 
 
L’aggravation de certaines caractéristiques cliniques des femmes enceintes (âge, poids) et 
l’augmentation de la prévalence du diabète gestationnel (DG) poussent à dépister le DG le plus tôt 
possible pour éviter chez la mère et le fœtus les complications à court et à long terme. Le dépistage 
du DG est recommandé à 24-28 semaines de grossesse, et le plus souvent un test de tolérance à 
50g de glucose (TTG) est réalisé. Pour les femmes qui ont des facteurs de risque, ce test doit être 
effectué plus précocement, habituellement pendant le premier trimestre de la grossesse. Cette 
dernière recommandation est peu suivie, d’autant qu’il n’y a pas de consensus international sur le 
dépistage du DG pendant le premier trimestre de la grossesse. 
 
Objectifs. 1) Définir au premier trimestre de la grossesse la valeur de la glycémie du TTG qui 
prédit le diagnostic de DG à 24-28 semaines avec une sensibilité et une spécificité optimales à 
l’aide d’une courbe ROC. 2) Déterminer si la glycémie du TTG au premier trimestre est un facteur 
prédictif indépendant du DG. 
 
Méthodes. Étude prospective de cohorte. Les facteurs d'inclusion étaient : âge ≥ 18 ans et âge 
gestationnel entre 6 et 13 semaines après la dernière menstruation. Les TTG ont été effectués à la 
première visite prénatale. Une deuxième visite était programmée à 24-28 semaines pour faire une 
hyperglycémie provoquée par voie orale (HGPO) et donc un éventuel diagnostic de DG. Les 
critères utilisés pour ce diagnostic étaient ceux de l’Association américaine du diabète. 
 
Résultats. Les TTG ont été faits à 9,1±2,0 semaines et les HGPO à 26.5±1.1semaines chez 1180 
femmes (28,2±4,4 ans, IMC : 25,2±5,5 kg/m2). Un DG a été diagnostiqué chez 100 (8,4%) 
participantes. La valeur de glycémie du TTG à 5,6 mmol/L a prédit le DG avec une sensibilité de 
84,1% et une spécificité de 62,3%, tandis que la valeur prédictive positive était de 0,121 et la 
valeur prédictive négative de 0,985. Cette valeur de 5,6 était indépendamment associée au DG 
(OR=2,806, IC 95%: 1,98 à 3,97, p <0,001). Comparé à d'autres facteurs de risque, le TTG était le 
plus puissant prédicteur indépendant du DG (OR=1,767, IC 95%: 1,52 à 2,05, p <0,001). 
 
Conclusions. Au premier trimestre, la valeur glycémie de 5.6 mmol/L du TTG prédit avec une 
bonne sensibilité et spécificité l’apparition d’un DG à 24-28 semaines. La glycémie du TTG au 
premier trimestre est le plus puissant prédicteur indépendant de DG. 
 
Mots clés : diabète gestationnel, DG, dépistage, 1er trimestre, grossesse, TTG, OGTT. 
  
 
 
 
SUMMARY 
Early Screening of Gestational Diabetes Mellitus 
 
by 
Masoud Mahdavian 
Clinical Sciences Program 
 
Thesis presented at the Faculty of Medicine and Health Sciences for the obtention of Master 
degree diploma [maitre ès sciences] (M.Sc.) in Clinical Sciences, Faculty of medicine and health 
sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada, J1H 5N4 
 
The changes in clinical characteristics of pregnant women and an increase in the prevalence of 
gestational diabetes mellitus (GDM) warrant the importance of screening as early as possible in 
order to possibly prevent short and long-term complications in both the mother and fetus. GDM 
screening is recommended at 24-28 weeks of pregnancy, using a 50g glucose challenge test (GCT) 
although women with multiple risk factors are expected to be assessed “early” in pregnancy, a 
recommendation poorly followed. Most importantly, there is no universal agreement currently in 
place for GDM screening, particularly during the first trimester of pregnancy.  
 
Objectives. 1) To define the cut-off value of GCT during the first trimester in order to predict 
GDM diagnosed at 24-28 weeks of gestation with optimal sensitivity and specificity using ROC 
curve. 2) To determine if GCT during the first trimester of pregnancy is an independent predictor 
of GDM diagnosed at 24-28 weeks gestation.  
 
Methods. This is a prospective cohort study. Women were recruited at their first prenatal visit. 
Inclusion factors were: age ≥ 18 years and gestational age between 6 and 13 weeks from their last 
menstrual period. GCT were performed at the first prenatal visit. The second visit was scheduled 
at 24-28 weeks for the diagnostic 75g oral glucose tolerance test (OGTT). GDM diagnosis was 
made in accordance with the American Diabetes Association guidelines. A variety of statistical 
analysis including multivariate logistic regression models and ROC curve were used to address 
the aims of the study. 
 
Results. Participants (n=1180, age: 28.2±4.4 years, BMI: 25.2±5.5 kg/m2) underwent GCT at 
9.1±2.0 weeks and OGTT at 26.5±1.1 weeks of gestation. GDM was diagnosed in 100 (8.4%) 
women. The cut-off value of 5.6 mmol/L predicted GDM with 84.1% (75.4-92.7) sensitivity, 
62.3% (59.5-65.1) specificity, while the positive predictive value was 0.121 (0.091-0.150) and the 
negative predictive value was 0.985 (0.975-0.994). This 5.6 value was independently associated 
with GDM (OR=2.806, 95% CI: 1.98-3.97, p<0.001). Compared to other risk factors, GCT was 
the strongest independent predictor of GDM (OR=1.767, 95% CI: 1.52-2.05, p<0.001). 
 
Conclusions. The cut-off value of 5.6 mmol/L has the optimal sensitivity and specificity for the 
GCT during the first trimester to predict GDM at 24-28 weeks of gestation according to ADA 
guidelines. GCT during the first trimester is the strongest independent predictor of GDM at 24-28 
weeks of gestation.  
 
Keywords: Gestational diabetes mellitus, GDM, screening, 1st trimester, pregnancy. 
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INTRODUCTION 
1.1 Definition and Epidemiology 
Pregnancy is characterized by a progressive increase in nutrient-stimulated insulin responses 
despite an only minor deterioration in glucose tolerance, consistent with progressive insulin 
resistance (Butte, 2000). Gestational diabetes mellitus (GDM) is a condition in women who 
have glucose intolerance with onset or first recognition during pregnancy (Canadian Diabetes 
Association Clinical Practice Guidelines Expert Committee, 2013, Metzger and Coustan, 
1998).   
 
The prevalence of GDM is estimated between 2% and 18% depending upon the population 
studied and the diagnostic tests employed (Kim et al., 2002). We participated in this debate. 
In a cohort of 459 pregnant women recruited prospectively, we showed that the prevalence 
of GDM (diagnosed with 75g oral glucose tolerance test – OGTT - in a one-step universal 
procedure) is multiplied 3.6 fold (Mahdavian et al., 2010) when the International Association 
of Diabetes in Pregnancy Study Group (IADPSG) cut-off values vs. those recommended in 
2010 by the American Diabetes Association (ADA) were used (American Diabetes 
Association, 2010, IADPSG consensus panel, 2010). In addition to the cut-off values 
questioning, several parameters influence the detection of GDM by affecting sensitivity and 
specificity of GCT and OGTT such as sample handling and processing times, and diurnal 
variations in the tests results (Ardilouze, Mahdavian et al., 2012). All these factors should be 
considered in the interpretation of tests. Nonetheless, regardless of different diagnostic 
methods or cut-off values, GDM prevalence has doubled over the past 10 years in all ethnic 
populations and this seems to be related mainly to increasing weight gain (Dabelea et al., 
2005, Ferrara et al., 2004). Although Caucasian women have the lowest GDM risk, one study 
reported a 12.3% prevalence of GDM in 3,950 Italian women and an absolute 5.6% 
prevalence in women with low risk for GDM (Di Cianni et al., 2003).
 
Another study 
performed in the UK (Cosson et al., 2006)
 
found a 13% prevalence using universal screening 
versus 8% using a risk-factor approach.  
Recognition of diabetes for the first time during pregnancy corresponds to both unrecognized 
pre-gestational diabetes and any overt glucose intolerance occurring during this pregnancy. 
Pathogenesis of GDM is multifactorial; however, it is not completely clear. Both relative 
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diminished insulin sensitivity causing insulin resistance and β cell dysfunction causing 
reduced insulin release have been proposed (Singh et al., 2015, Al-Noaemi and Shalayel, 
2013). These changes are affected by multiple factors including but not limited to Human 
Placental Lactogen secretion, expression of sex hormone binding globulin (SHBG), cytokine 
release such as MIF, TGF- β (Singh et al., 2015, Li et al., 2015, Marcantoni et al., 2015). 
GDM may also occur in women with a background of chronic insulin resistance to which the 
insulin resistance of pregnancy is partially additive. Sequential measurements of insulin 
sensitivity performed in the same women before pregnancy, early in the second trimester and 
in the third trimester have documented insulin resistance in both lean and obese women who 
eventually develop GDM (Catalano et al., 1999 and Catalano et al., 1993).
 
Changes in 
carbohydrate homeostasis have been described as early as at six weeks’ gestation and, 
consequently, some women with early onset of GDM could have pregnancy-induced glucose 
intolerance (Freinkel, 1980).
  
These findings partially explain why GDM develops not only 
in overweight or obese women but also in lean women, which suggests that normal weight 
women should be screened for GDM, hypothetical procedure which went against many 
recommendations at the time we initiated the present study, in particular those of the ADA 
(see below). 
 
1.2 GDM Risk Factors 
Several risk factors (RFs) have been described for GDM. Until recently the ADA would state 
that women with all of the following characteristics were at low risk for GDM development: 
age < 25 years, normal body weight before pregnancy, Caucasian, no known diabetes in a 
first degree relative, no history of abnormal glucose intolerance and no history of abnormal 
obstetrical outcome (American Diabetes Association, 2009). However, the more recent 2014 
ADA guidelines recommend that the RFs for type 2 diabetes (T2D) should be considered for 
GDM screening (American Diabetes Association, 2014).   
 
Age ≥ 35 years, body mass index (BMI) ≥ 30 kg/m2, ethnicity, polycystic ovary syndrome, 
previous GDM, history of macrosomic infant or current fetal macrosomia or 
polyhydramnios, acanthosis nigricans and corticosteroid use have been considered as GDM 
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RFs by the Canadian Diabetes Association (CDA) (Canadian Diabetes Association Clinical 
Practice Guidelines Expert Committee, 2013). 
 
1.3 GDM Complications 
GDM carries short and long-term health risks for both the fetus and the mother. Short-term 
fetal complications include death in utero, prematurity, large (LGA) or small (SGA) for 
gestational age neonates, macrosomia, dystocia, admission to neonatal nursery and intensive 
care units, hypoglycemia, hypocalcaemia, convulsions and hyperbilirubinemia (Metzger and 
Coustan, 1998, Coustan, 2010). The short-term complications for the mother include 
preeclampsia, antenatal admission, hydramnios, induced labor and caesarean section 
(Metzger and Coustan, 1998). In addition, GDM is a forerunner of T2D (Kim et al., 2002). 
It was shown in the Diabetes Prevention Program Study in 3,234 pre-diabetic subjects, that 
a history of GDM increases by 74% the risk of developing T2D (Knowler et al., 2002). 
 
The focus of the impact of GDM on offspring has now shifted from the prevention and care 
of perinatal morbidity to the long-term prevention of metabolic diseases. GDM, as maternal 
BMI, is a risk factor contributing to the worldwide epidemics of obesity and T2D in 
childhood ‒ and adulthood (Dabelea et al., 2000, Dabelea and Pettitt, 2001) ‒ although these 
epidemics are still not completely understood. Thus, prevention is the key. However, it 
requires thorough comprehensive screening strategies. 
 
Furthermore, the level of hyperglycemia and the time of screening/diagnosis matter. Women 
with GDM diagnosed early in pregnancy are more hyperglycemic and at higher risk for 
obstetrical and neonatal complications during the current pregnancy and for recurrent GDM 
in future pregnancies (Ben-Haroush et al., 2004, Berkowitz et al., 1992).
 
The Hyperglycemia 
and Adverse Pregnancy Outcome (HAPO) Study showed in 23,325 women (age: 29.2±5.8, 
BMI 27.7±5.1 kg/m2) that the relationship between maternal glycaemia and fetal 
hyperinsulinemia, LGA, cesarean-section rate and neonatal hypoglycemia, adverse maternal 
and fetal outcomes is a continuum (The HAPO Study Cooperative Research Group, 2008).  
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Interestingly, the most frequent short-term complications are preventable in neonates, even 
with moderately hyperglycemic mothers, as shown by the Australasian Carbohydrate 
Intolerance in Pregnancy Study (ACHOIS) (Crowther et al., 2005).
 
In this study, performed 
in women with glucose intolerance diagnosed during pregnancy (subjects with pre-
gestational diabetes were excluded), the number to treat was 34 to avoid 1 serious perinatal 
complication, 11 and only 9 to avoid LGA and macrosomia, respectively in the neonate 
(Crowther et al., 2005).
 
This study demonstrated the clinical validity of screening for GDM. 
However, the impact of universal “early” screening remains to be demonstrated. 
 
Data from several studies suggest that exposure of the fetus to the mother’s GDM 
environment confers a risk for T2D and obesity during childhood and adolescence that 
overrides any genetically transmitted susceptibility. Maternal antenatal glycaemia is related 
to the long-term risk of obesity, metabolic syndrome, abnormal levels of inflammatory and 
coagulation markers, and diabetes in the offspring (Boney et al., 2005, Dabelea et al., 2000a, 
Dabelea et al., 2000b Dabelea and Pettitt, 2001).  
 
The concept of ‘metabolic programming’ (Ismail-Beigi et al., 2006)
 
was first illustrated in 
Pima Indians (Dabelea et al., 2000b)
 
and thereafter in offspring of GDM women in the USA 
(Boney et al., 2005, Metzger, 2007),
 
Canada (Keely et al., 2007),
 
and Denmark (Clausen et 
al., 2007).
 
However, these cross-sectional studies failed to control for maternal disease 
history and genetic background since heredity is a major epidemiologic risk factor for type 2 
diabetes. Exclusion of confounding genetic factors is a key element to establish the role of 
GDM as an independent marker of cardio-metabolic risk in GDM offspring. Our team is 
carrying out a study that aims to demonstrate in children that metabolic syndrome and cardio-
metabolic markers are more frequent in offspring of GDM mothers than in their siblings born 
from non-GDM pregnancies. 
 
In addition, the exact effects of GDM and maternal obesity remain to be established (Gillman 
et al., 2003, Schaefer-Graf et al., 2005).
 
Compounding this worrisome future is a suggestion 
that treatment of GDM decreases the prevalence of obesity in 5-7 year-old offspring (Hillier 
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et al., 2007).
 
This data, taken together with the “Programming hypothesis,” points to early 
screening and treatment of GDM. 
 
1.4 Screening test 
Many women with GDM are asymptomatic; however, GDM has a significant impact on them 
and their offspring (The HAPO Study Cooperative Research Group, 2008). Most of these 
short and long-term complications are preventable (Crowther et al., 2005, Hillier et al., 
2007). Screening test is used to determine individual who may have a disease in apprently 
healthy and asymptomatic people. In addition, a screening test requires to be done when it 
can fulfil Wilson’s criteria (Wilson and Jungner, 1968), and these criteria must be attained: 
1) early screening, 2) in asymptomatic people, 3) validity and reliability, 4) affordable costs, 
5) acceptance, and 6) follow-up services. A screening test does not establish a diagnosis. The 
major benefit of a screening test is to identify an asymptomatic person at risk for the disease 
to reduce the mortality and morbidity of the disease of interest. 
 
1.5 Diagnostic test 
A positive screening test is usually followed by a diagnostic (confirmatory) test to verify a 
definitive diagnosis (Kanchanaraksa & Diener-West, 2008). A diagnstic test is used to verify 
the presence or absence of a disease when a person has signs or symptoms of the disease of 
interest (Kanchanaraksa & Diener-West, 2008). The best available test to determine a person 
has the disease of interest is considered as the “Gold Standard test”. Validity and reliabity of 
other tests are compared to the gold standard test to diagnose the disease of interest 
(Kanchanaraksa & Diener-West, 2008).  
 
1.6 Sensitivity and Specificity 
Sensitivity and specificity are two indices of validity of a test when the outcome and the 
exposure are categorical variable (Szklo and Nieto, 2014). An ideal screening test should 
have both high sensitivity and high specificity (Bonita et al., 2006). Sensitivity of a test is 
the ability of a test to determine accurately people who have the disease of interest. 
Specificity of a test is the ability of a test to determine accurately people who do not have the 
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disease of interest (Szklo and Nieto, 2014). A more sensitive test usualy is initially the first 
step to detect more possible cases; however, it will increase the number of false positive 
cases. Therefore, it is followed by a more specific (diagnostic or confirmatory) test. A 
sequential screening (two step) will increase net gain in specificity of the screening 
(Kanchanaraksa & Diener-West, 2008). Sensitivity and specificity of the test are not 
dependent on the disease prevalence.  
 
1.7 Positive and Negative Predictive values, likelihood ratio 
To interpret a test result, healthcare providers need to know about the positive and negative 
predictive values. A positive predictive value (PPV) is the proportion of true positive among 
people who have a positive test result. A negative predictive value (NPV) is the proportion 
of true negative results among people who have a negative test result. PPV and NPV are 
affected by the prevalence of the disease in the population that is being tested. If the 
prevalence of a disease is high, it is more possible that the person with a positive test has a 
true positive result. Healthcare providers also need to know the positive and negative 
likelihood ratios (LRs) which are also used to assess the value of a positive or negative 
diagnostic test (Szklo and Nieto, 2014). A positive LR gives us the probability of a positive 
finding in a patient with the disease of interest compare to the probability of the same finding 
in a subject without the disease of interest (McGee, 2002). 
 
 Disease + Disease - Total 
Positive test result a (True Positive) b a + b 
Negative test result C d (True Negative) c + d 
Total a + c b + d a + b + c + d 
    
Sensitivity= a / (a + c)           Specificity= d / (b + d)    PPV= a / (a + b)            NPV= d / (c + d) 
 
 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝐿𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 𝑟𝑎𝑡𝑖𝑜𝑛 =
𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑓𝑖𝑛𝑑𝑖𝑛𝑔 𝑖𝑛 𝑎 𝑝𝑎𝑡𝑖𝑒𝑛𝑡 𝑤𝑖𝑡ℎ 𝑑𝑖𝑠𝑒𝑎𝑠𝑒 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡
Probability of the finding in a subject without the disease of interest
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1.8 ROC Curve 
If the test results are reported as ordinary or continuous scale, the different cutoff (threshold) 
values affect the sensitivity and specificity of the test, and specificity is inversly related with 
sensitivity (Hajian-Tilaki, 2013). Receiver operating characteristic (ROC) curve is the plot 
of sensitivity versus 1-specificity. The area under the ROC curve (AUROC) is the measure 
of the accuracy of the test (Hanley and McNeil, 1982, Hajian-Tilaki, 2013). This curve has a 
pivotal role in the assessment of a diagnostic test to determine the optimal cutoff value 
(Hajian-Tilaki, 2013). This type of analysis has been used in many clinical studies to assess 
the diagnostic ability of the tests (biomarkers and imaging studies) to differentiate population 
with the disease from healthy ones (Hajian-Tilaki, 2013). Furthermore, it is commonly used 
to predict the risk of an adverse event (Hajian-Tilaki, 2013). 
 
1.9 Current ADA and CDA Screening and Diagnosis Recommendations 
The ADA recommends that pregnant women with RFs for T2D should be screened for 
previously unrecognized T2D during the first prenatal visit. Otherwise, GDM screening 
should be undertaken on pregnant women who do not have a history of diabetes at 24-28 
weeks of gestation (American Diabetes Association, 2014). The CDA recommends a 
universal screening for GDM at 24-28 weeks of gestation. However, women with multiple 
RFs should be screened during the first trimester (Canadian Diabetes Association Clinical 
Practice Guidelines Expert Committee, 2013). 
 
Both the ADA and CDA guidelines currently recommend the one-step or two-step 
approaches. In the one-step approach, there is no requirement for a 50g glucose challenge 
test (GCT) and pregnant women directly undergo a 75g oral glucose tolerance test (OGTT). 
The 75g-OGTT results are interpreted according to the IADPSG guidelines with GDM 
diagnosed if any plasma glucose (PG) value exceeds the thresholds presented in Table 1 
(IADPSG Consensus Panel, 2010).  
 
In the two-step approach, pregnant women are initially tested with a GCT. If the GCT plasma 
glucose (PG) value is above the threshold (≥ 7.8 mmol/L), women will proceed to a 75g-
OGTT (CDA preferred approach and NIH consensus of the ADA [NDDG]) or a 100g-OGTT 
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(NIH consensus of the ADA [Carpenter/Coustan]). The PG results of the second step are 
interpreted according to thresholds presented in Table 1. According to ADA, GDM diagnosis 
is made when at least two of the four 100g-OGTT PG values exceed thresholds shown in 
Table 1 (American Diabetes Association, 2014). However, according to CDA, GDM is 
diagnosed if one 75g-OGTT PG value meets or exceeds the recommended threshold 
(Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, 2013).  
 
Table 1. Threshold values for the screening and diagnosis of GDM by ADA and CDA. 
Method ADA (mmol/L) CDA (mmol/L) 
One-step 
(IADPSG 
Consensus) 
75g-OGGT 
Two-step  
(NIH Consensus) 
One-step 
(IADPSG 
Approach) 
75g-OGGT 
Two-step 
(Preferred 
Approach) 
75g-OGTT 
Carpenter/ 
Coustan 
100g-OGTT 
NDDG 
75g-OGGT 
GCT NA ≥7.8 ≥7.8 NA ≥ 7.8  
Fasting PG ≥ 5.1 >5.3 >5.8 ≥ 5.1 ≥ 5.3 
1hr 75g-OGTT ≥ 10.0   ≥ 10.0 ≥ 10.6 
2hr 75g-OGTT ≥ 8.5   ≥ 8.5 ≥ 9.0 
1hr 100g-OGTT  >10.0 >10.6   
2hr 100g-OGTT  >8.6 >9.2   
3hr 100g-OGTT  >7.8 >8.0   
ADA: American Diabetes Association 2014, CDA: Canadian Diabetes Association 2013, 
NDDG: National Diabetes Data Group, IADPSG: International Association of Diabetes and 
Pregnancy Study Groups, NA: Not applicable and GCT is not necessary in this approach.   
 
1.10 Why Early Screening? 
Although there are still controversies surrounding the screening and consequences of GDM 
(Sermer, 2003, Wen et al., 2000, Ouzilleau et al., 2003, Brody et al., 2003),
 
there is a general 
agreement that screening should be performed as soon as possible in at-risk women 
(American Diabetes Association, 2014, Canadian Diabetes Association Clinical Practice 
Guidelines Expert Committee, 2013). 
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Nowadays, universal early GDM screening sounds crucial; the reason could be simply 
because it is recommended by most diabetes professional associations in a large part of the 
population since aging and overweight are RFs. The common assumption that “the earlier 
the treatment, the better the outcomes” is another reason, although weaker. However, several 
strong lines of evidence reinforce the universal early screening policy hypothesis.  
 
First, clinical characteristics of pregnant women have changed (Ferrara et al., 2004).
 
Over 
the last decades, RFs for insulin resistance have increased rapidly in the population of 
childbearing women. The percentage of overweight and obese women of childbearing age 
has increased tremendously, reaching a whopping 43% in Canada (Tjepkema, 2006, Shields 
et al., 2011).
 
This weight gain causes a parallel increase in insulin resistance, a condition 
contributing to GDM (Kauffman et al., 2006).
 
Moreover, pregnancy is occurring at an older 
age (Ferrara et al., 2004) and age is another well-known risk factor for GDM (Ben-Haroush 
et al., 2004).
 
Both of these trends (weight gain and aging) increase the risk and precocity of 
the GDM onset and underline the importance of early screening.  
 
Second, the proportion of women with undiagnosed T2D is also on the rise in the North 
American population (Casson et al., 2006).
 
It was also reported that T2D represents 27.3% 
of pre-gestational diabetes in a United Kingdom population including, indeed, a large ethnic 
(Pakistanis and South India) proportion (Casson, 2006). 
 
Third, early-onset GDM is a serious condition. Women with early-onset GDM are more 
likely to be hypertensive, to have higher glycemic values, and to need insulin therapy than 
those in whom diabetes develops later (Bartha et al., 2000, Svare et al., 2001).
 
In one Spanish 
study, all cases of neonatal hypoglycemia and perinatal death occurred within the early-onset 
group (Bartha et al., 2000).
 
 
Fourth, testing in early pregnancy potentially allows for earlier and more efficient 
intervention (diet, exercise and pharmacotherapies). One explanation to the current 
controversy surrounding the benefits of GDM screening and treatment might be that 
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screening at 24-28 weeks of gestation is too late. Nonetheless, it has been demonstrated that 
treatment of GDM is effective in reducing short-term (Crowther et al., 2005)
 
and long-term 
complications (Hillier et al., 2007). Taken together, the above-mentioned evidence provides 
strong justification for early screening. 
 
1.11 Review of Previous Published Articles Related to Early Screening  
We found six papers focusing on early GDM screening. 
1) In 1986, Benjamin et al.
 
performed GCTs during the first trimester (weeks 6 to 13) and a 
100g-OGTT (American Diabetes Association standards) during the second
 
(weeks 14 to 26) 
and third
 
trimesters (weeks 27 to term) in a small cohort of 101 high-risk women aged 26.4±6 
years, classified obese although BMI and weight were not specified. The third
 
trimester 100g-
OGTT was the diagnostic test. With a 7.7 mmol/L threshold, the sensitivity and specificity 
of the GCT were 88% and 73%, respectively, using the third
 
trimester 100g-OGTT results 
for the GDM diagnosis. However, the GCT sensitivity was only 25% when GDM women 
were discovered by a positive 100-OGTT during the second
 
trimester. Similar issues were 
found when the GCT threshold was > 8.25 mmol/L. Therefore, authors concluded that 
guidelines for GDM screening should include follow-up with a third
 
trimester OGTT on all 
patients who test positive at screening, even in the presence of normal second
 
trimester 
OGTT, and that OGTT should be deferred until the early third
 
trimester (Benjamin et al., 
1986). However, because the number of events (8) was very low, one ponders the validity 
and conclusions of this pioneering study.  
 
2) Nahum and Huffaker (1990) performed GCT in first and in early third trimesters in a small 
cohort of 124 American women described as white (61%) and non-white, normal weight 
(47%) and obese. They found a correlation (r=0.54, P= 0.000001) between the first
 
trimester 
and the third
 
trimester (28-32 weeks) GCTs. The correlation was stronger among white 
people (r= 0.67, P= 0.000001). A 100g-OGTT was performed in subjects with 1h post GCT 
≥ 7.4 mmol/L. Nine (7%) were found to have GDM during the third
 
trimester. No one was 
diagnosed with GDM among white women with first trimester GCT value < 6.1mmol/L. 
They recommended there is no yield from a third trimester GCT when the first trimester GCT 
is less than 6.1 mmol/L (NPV= 91%). In addition, when the first trimester GCT is > 7.8 
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mmol/L, it has a high predictive value (PPV= 91%) for an abnormal third trimester GCT 
which requires a subsequent OGTT (Nahum and Huffaker, 1990). Again, the limited number 
of events and the heterogeneity of the sample bring into question the validity of these 
findings.  
 
3) Nahum et al.
 
(2002) again found a correlation between the GCT results at the end of the 
first
 
trimester and at week 28 in 255 (out of 439 enrolled) normal-weight pregnant women 
aged 27.6±6.2 years (BMI: 23.9±5.2 kg/m2)
 
except in 37 Pacific Islanders with a BMI 
28.9±6.8 kg/m2
 
who had the lowest mean PG post GCT at 5.6±1.5 mmol/L. In subjects with 
1-h post GCT ≥ 7.4 mmol/L, a 100g-OGTT diagnostic test was performed. GDM was 
diagnosed in 10% of subjects (only 25 women). Patients with first GCT PG ≥ 7.5 mmol/L 
had a positive predictive value showing a 55% risk of developing diabetes during pregnancy, 
while the risk was 0.6% in patients with values ≤ 6.1 mmol/L (Nahum et al., 2002). However, 
a plasma hexokinase glucose determination was used during the second
 
trimester GCT, 
whereas capillary whole-blood reflectance glucometer was used at 28 weeks.  
 
4) Bhattacharya et al. (2002) studied an Indian population (n=458) of non-diabetic women 
[100g-OGTT early in the first trimester, Coustan’s criteria (Coustan et al., 1989)] with BMI 
< 25 kg/m2. The 100g-OGTT diagnostic test was performed in only 133 women with GCT 
≥ 7.8 mmol/L at third trimester. GDM was found in 38 women (8.3% of the cohort). When 
the first trimester GCT PG was under 5.5 mmol/L, no subject tested positive for GDM during 
the third trimester OGTT. When the first trimester GCT glucose was ≥ 7.8 mmol/L (n=18), 
72% (n=13) cases tested positive for GDM. The GCT during the first trimester was predictive 
(correlation coefficients= 0.38) of the early third trimester OGTT result (substantial 
correlation for 0.20< CC<0.70). However, it is well established that the Indian population is 
predisposed to cardiovascular disease, T2D and visceral obesity (Retnakaran et al., 2006). 
Moreover, it was reassessed that international standards are not appropriate for Indian women 
(Kulkarni et al., 2007). Accordingly, the external validity of this study is very low.  
 
5) Maegawa et al.
 
(2003) measured GCT and OGTT during the first
 
trimester in a Japanese 
population (n=749, age 28.9±4.1 years, BMI 21±2.9 kg/m2). Subjects with normal results 
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were tested again at 24–28 weeks of gestation with GCT and 75g-OGTT. Only 22 women 
(2.9%) tested positive for GDM (Japan Diabetes Society and the Japan Society of Obstetrics 
and Gynecology criteria) with OGTT. Among those 22 women who diagnosed with GDM, 
14 were predicted with the first
 
trimester (threshold: 7.2 mmol/L) and 8 with the second
 
trimester GCT (threshold: 7.2 mmol/L). This study concluded that the majority of cases of 
GDM were detected during the first
 
trimester with a positive GCT. However, the absence of 
the clear definition of first
 
trimester (gestational weeks) and the low prevalence of GDM were 
both weaknesses of the study. In addition, the OGTT cutoff values for the GDM definition 
were different with ADA and CDA guidelines. 
 
6) Bito et al.
 
(2005) studied a cohort of 163 women having one or two risk factors for GDM 
(mostly familial history of diabetes, obesity and age). A 75g-OGTT was performed at ≤ 16 
weeks, 24-28
 
weeks and 32-34
 
weeks and the World Health Organization (WHO) criteria 
were used for the GDM diagnosis. Using logistic regression analysis and ROC curves, it was 
determined that at 14 weeks, fasting (5.0 mmol/L) and 2-hr 75g-OGTT (6.2 mmol/L) glucose 
are cut-off values under which GDM at 24-28 weeks is unlikely. The best combined cut-off 
values to exclude subsequent GDM were ≤ 5.3 mmol/L (fasting) and ≤ 6.8 mmol/L (2-hr post 
load) (Bito et al., 2005). However, using these cut-off values, the lowest false-positive rate 
was very high, 73.5% at 24-28
 
weeks. Results from this study must be considered with 
caution since this Hungarian cohort (age: 29±5 years, pre-gestational BMI: 29.5±5.6 kg/m2) 
had a noteworthy and surprising risk for GDM: 54% of the 163 women developed GDM at 
some point during pregnancy although no risk factor was significant for the prediction of 
GDM. This suggests that risk factors are useful to identify at-risk women yet they have low 
predictive value (Griffin et al., 2000).
 
 
  
There are several important drawbacks in these above-mentioned studies. First of all, there 
is an extended definition of first
 
trimester in the first, second and fourth papers. Two other 
papers (Bartha et al., 2000
 
and Meyer et al., 1996)
 
were not included in this review because 
screening was performed at 18 weeks and 22 weeks, respectively. In addition, the CDA 
recommended threshold (7.8 mmol/L) was seldom used (in the first and fourth papers). 
Furthermore, all papers were underpowered as previously explained.  
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Although some reported sensitivities or specificities seem high, 95% confidence intervals 
were not reported and are expected to be very large (for sensitivity and likelihood ratios, for 
example). The fourth and fifth studies are encouraging but were performed on Japanese and 
Indian women, respectively. In these studies, women with a negative GCT were not assessed 
and excluded although it was shown that 6.3% of women with a GCT < 7.8 mmol/L develop 
GDM (Di Cianni et al., 2003, Naylor et al., 1997). True GDM and pre-existing T2D were 
not differentiated in these studies. Another important weakness of these studies is the absence 
of blinding in their research design. None of these papers specify whether or not first 
screening results were blinded for the participants and/or the research team.  
 
The above-mentioned weaknesses have been considered in our study design. 
 
HYPOTHESIS 
Rational: As described in the above section, the escalating prevalence of obesity and the 
increasing age of pregnancy, both risk-factors to increase insulin resistance, strengthen the 
need to find an appropriate method to screen universally for GDM in the early stage of 
pregnancy. Moreover, it would be very appropriate to identify early on women who will later 
develop GDM, in order to prevent the mother and her fetus from the appearance of GDM as 
well as the short and long-term complications of GDM, assuming that “the earlier the 
treatment, the better the outcomes”. However, in early pregnancy there is no approved and 
generalizable screening method to predict GDM with high sensitivity and acceptable 
specificity. Such determination of prediction criteria would enable healthcare providers to 
distinguish pregnancies at high risk of GDM from those at low risk. This criteria would allow 
for early intervention and prevention of GDM providing that the clinical validity of such 
approach is demonstrated in future study. 
 
Hypothesis: GCT plasma glucose value obtained during the first trimester is an independent 
predictor of GDM determined by 75g-OGTT at 24-28 weeks of gestation despite presence or 
absence of other risk factors for GDM. 
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OBJECTIVES 
3.1 Objective No. 1  
To determine if GCT obtained during the first trimester of pregnancy is an independent 
predictor of GDM diagnosed by 75g-OGTT at 24-28 weeks of gestation.  
3.2 Objective No.  2  
To define the cut-off value of the one hour GCT plasma glucose value obtained during the 
first trimester in order to predict GDM with optimal sensitivity and specificity as diagnosed 
by 75g-OGTT at 24-28 weeks of gestation. 
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ARTICLE 1 
First-trimester 50g-glucose challenge test: A robust predictor of gestational diabetes 
mellitus at 24-28 weeks of pregnancy. 
 
Auteurs de l’article : Masoud Mahdavian,  Marie-France Hivert, Julie Menard, Jean-Marie 
Moutquin, Annie Ouellet, Patrice Perron, Ghislaine Houde, Jean-Patrice Baillargeon, Jean-
Luc Ardilouze 
 
Statut de l’article : submitted to JAMA. 
 
Avant-propos : my contribution in this article was in acquisition, analysis and interpretation 
of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript 
for important intellectual content. 
 
Résumé en français  
Objectif : Déterminer au premier trimestre de la grossesse quelle est la valeur de la glycémie 
d’un test de tolérance à 50g de glucose (TTG) qui permet de prédire l’apparition d’un diabète 
gestationnel (DG) à 24-28 semaines. 
 
Méthodes. Étude prospective d’une cohorte de femmes enceintes (âge ≥ 18 ans, sans diabète 
connu). Les TTG étaient effectués avant la 14e semaine de grossesse et les hyperglycémies 
provoquées par voie orale (HGPO) à 24-28 semaines. Les résultats des TTG étaient gardés 
en aveugle. Le diagnostic de DG était posé sur l’HGPO, en utilisant les critères 2014 de 
l’Association américaine du diabète.  
 
Résultats. Les dossiers de 1180 femmes (âge : 28,2±4,4 ans, IMC : 25,2±5,5 kg/m2) ont été 
analysés. Les TTG ont été faits à 9,1±2,0 semaines et les HGPO à 26.5±1.1semaines. Un DG 
a été diagnostiqué chez 100 (8,4%) participantes. La glycémie post-TTG (5,6 mmol/L) 
prédisait le DG avec une sensibilité de 84,1% et une spécificité de 62,3%. Outre la glycémie 
post-TTG à 5.6 mmol/L, les autres prédicteurs indépendants du DG étaient les antécédents 
d’intolérance au glucose, l'âge ≥ 35 ans et l’IMC ≥ 25 kg/m2. Le TTG était le meilleur 
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marqueur de DG : après ajustement pour les autres facteurs prédictifs, la glycémie post-TTG 
≥ 5.6 mmol/L multipliait les risques de DG par 7.8 (IC 95% de 4,15 à 16,1, p <0,001). 
 
Conclusions. Le TTG au premier trimestre est un puissant facteur prédicteur de DG à 24-28 
semaines de gestation. Nous proposons qu’il soit utilisé pour identifier les femmes à risque 
élevé de DG à qui des soins préventifs pourraient être offerts.  
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ABSTRACT 
Objectives. To determine first-trimester 50g-glucose-challenge test (GCT) glucose cut-off 
value that is most predictive of development of gestational diabetes mellitus (GDM)  
diagnosed at 24-28 weeks using 75g oral glucose tolerance test (OGTT), according to 2014 
ADA thresholds.  
Research Design and Methods. Population-based, prospective cohort study of pregnant 
women (age ≥18 years, no diabetes prior to pregnancy). GCT was performed before 14th 
week of pregnancy and diagnostic OGTT at 24-28 weeks. GCT results were blinded until 
OGTT for GDM diagnosis. 
Results. Complete data from 1180 women were analyzed. Women were 28.2±4.4 years old, 
and had a BMI of 25.2±5.5 kg/m2.  They completed GCT at 9.1±2.0 weeks of gestation and 
OGTT at 26.5±1.1 weeks. A total of 100 (8.4%) women were diagnosed with GDM. The 1h-
glucose post-GCT cut-off value of 5.6 mmol/L predicted GDM with 82.0% (74.5-89.5) 
sensitivity and 60.8% (57.9-63.7) specificity. The significant independent clinical predictors 
of GDM measured in our study were GCT result ≥5.6 mmol/L, history of abnormal glucose 
tolerance, age ≥35 years and BMI ≥ 25 kg/m2, among which GCT was the strongest predictor. 
After adjustment for these predictors, a GCT ≥5.6 mmol/L increased the odds of GDM 7.8 
folds (95% CI of OR: 4.15-16.1, p<0.001). 
Conclusions. First-trimester GCT is a strong predictor of GDM at 24-28 weeks of gestation. 
We propose that first-trimester GCT could be used to identify women at high-risk for GDM 
and to offer them appropriate preventive care. 
  
Keywords: Gestational diabetes mellitus, GDM, screening, predicting, 1st trimester, 
pregnancy 
 
Trial Registration: NCT01026675, ClinicalTrials.gov 
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Introduction 
Clinical characteristics of pregnant women have changed. More and more women delay 
starting a family (Kjos and Buchanan, 1999) and the proportion of childbearing-age women 
who are overweight and obese has significantly increased (Gingras et al., 2012, Coustan, 
1996). The prevalence of gestational diabetes mellitus (GDM) and pre-existing glucose 
intolerance or diabetes has also sharply risen (Ferrara, 2007, Lawrence et al., 2008). Some 
studies report GDM prevalence as high as 10%, 12% and 28% in Caucasian, Japanese and 
Southeast Asia region populations, respectively (Jiwani et al., 2012). GDM is therefore a 
serious public health concern, the prevalence of which will in all likelihood only increase in 
coming years. Screening and prevention are thus cornerstone to reducing the short and 
perhaps long-term complications of GDM for mothers and their babies. 
 
However, screening recommendations remain the subject of ongoing debate (American 
Diabetes Association, 2014, Canadian Diabetes Association Clinical Practice Guidelines 
Expert Committee, 2013, Nankervis et al., 2014, Vandorsten et al., 2013). Meanwhile, 
prevention recommendations have yet to be firmly established. This is partly due to a lack of 
robust means to adequately identify those women at high risk of GDM early during 
pregnancy. For screening, the American Diabetes Association (ADA) and many others 
recommend the two-step strategy consisting of a universal 50g-glucose challenge test (GCT) 
at 24-28 weeks of gestation, although women with multiple risk factors should in fact be 
tested earlier (Canadian Diabetes Association Clinical Practice Guidelines Expert 
Committee, 2013, Nankervis et al., 2014, Vandorsten et al., 2013). When 1h-glucose post-
GCT results exceed a certain threshold, the value of which varies according to national and 
international professional associations or organizations, women then undergo a diagnostic 
75g or 100g oral glucose tolerance test (OGTT). Others however perform the one-step 75g-
OGTT approach according to the 2010 recommendations of the International Association of 
Diabetes and Pregnancy Study Groups, which have since been adopted by the ADA. This 
latter approach calls for the OGTT in all clinical settings of pregnancy i.e. early on in high-
risk pregnancies to detect diabetes, and at 24-28 weeks as part of a universal screening 
strategy (IADPSG Consensus Panel, 2010). 
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The “early-screening” expert recommendation suggests that the same GCT or OGTT plasma 
glucose (PG) cut-off values be used both at 24-28 weeks and earlier. For prevention purposes, 
it is currently unknown whether the GCT early on in pregnancy helps identify those women 
at high risk of developing GDM later on. 
 
Accordingly, the aims of this study were to 1) determine the first-trimester GCT cut-off value 
with optimal sensitivity and specificity to predict development of GDM as diagnosed by 
standard 75-g OGTT between 24 and 28 weeks of gestation; 2) determine if first-trimester 
1h-glucose levels post-GCT predict GDM incidence independently of traditional first-
trimester risk factors.  
 
Research Design and Methods 
We conducted a population-based prospective study of pregnant women receiving care at the 
Centre Hospitalier Universitaire de Sherbrooke (CHUS). The CHUS Research Ethics Board 
approved the study protocol and all participants gave written informed consent prior to their 
participation in accordance with the Helsinki declaration and all applicable laws and 
regulations.  
 
Inclusion criteria were age ≥ 18 years, gestational age between 6 and 13 weeks from last 
menstrual period, no diabetes prior to pregnancy, < 2 alcoholic drinks/day, no regular high-
intensity physical activity, singleton pregnancy, and otherwise good health status.   
 
Women were recruited between April 2009 and June 2012, during their first prenatal visit 
(V1) at the CHUS Blood Sampling in Pregnancy (BSP) Clinic. The BSP Clinic offers routine 
prenatal blood sampling, including GCT and OGTT. The BSP Clinic is also a clinical 
research platform ensuring first-rate healthcare and follow-up for pregnant women with 
GDM by highly-trained staff (Hivert et al., 2012). 
 
At V1, non-fasting women arrived between 8h30 AM and 3h30 PM. Weight was measured 
barefoot, in light clothing on a body composition analyzer (Tanita, TBF-300A, Tanita 
Corporation, Arlington Heights, IL) to the nearest 0.1 kg and height, with a stadiometer to 
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the nearest 0.01 m. BMI was calculated as weight (kg) divided by squared height (m2). 
Women self-reported their pre-gestational weight which was used to calculate pre-gestational 
BMI. In addition to age and BMI, other traditional GDM risk factors were documented (2010 
ADA guidelines) (American Diabetes Association, 2010): history of diabetes in first-degree 
relatives, personal medical history of abnormal glucose metabolism including previous 
GDM, ethnicity, and poor obstetrical outcomes such as previous delivery of a newborn with 
fever, infection, hypoglycemia, jaundice, respiratory problem, fraction or malformation, 
being admitted to the intensive care unit, or stillborn. 
 
Women were asked to drink a 300-ml 50g-glucose oral solution (Glucodex, Rougier Pharma, 
Mirabel, Qc, Canada) within 5 minutes. Each bottle contained 166.6 mg dextrose, as 
recommended. Over the next hour, women remained seated and venous PG was measured 
once the hour was up. An appointment was then set for the second visit (V2). No dietary or 
exercise counseling was provided. A qualified biochemist verified GCT results. These were 
kept blinded to the study team members and participating women until V2, except when PG 
reached ≥ 10.3 mmol/L. Pursuant recommendations from the Canadian Diabetes Association 
(CDA) at the time (Canadian Diabetes Association Clinical Practice Guidelines Expert 
Committee, 2013). 11 women with GCT 1h-glucose ≥ 10.3 mmol/L were considered as 
GDM, and thus were excluded and referred for usual care (Hivert et al., 2012). 
 
For V2, scheduled between 24 and 28 weeks of gestation, women were asked to fast during 
the 12 hours preceding their appointment. Anthropometric data were collected according the 
same standardized protocols described for V1. Blood samples were collected (fasting, at 1h 
and 2h post 300-ml 75g-glucose oral solution (Glucodex) drunk within 5 minutes). Each 
bottle contained 250 mg dextrose, as recommended. Women remained seated during the 2h 
wait. Those with GDM were referred for usual care (Hivert et al., 2012). 
 
Venous plasma glucose was measured using the oxidase method (Modular Analytics, Roche 
Diagnostics, USA) at the CHUS Biochemistry Laboratory. 
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The main outcome of this study was GDM diagnosed between the 24th and 28th weeks of 
gestation (V2), according to 2014 ADA recommended criteria: one glycaemia ≥ 5.1, 10.0 or 
8.5 mmol/L at time 0, 60 and 120 min post-glucose, respectively. This main outcome was 
pre-specified, before the initiation of the study. 
 
We reported continuous variables as means ± standard deviations and categorical variables 
as percentages with 95% confidence intervals. We tested for differences between women 
with or without GDM; unpaired Student’s t-tests were used for continuous variables and chi-
squared tests for dichotomous variables. P-values < 0.05 were considered statistically 
significant for all analyses. Under objective 1, we constructed a ROC curve using sensitivities 
and specificities calculated from results of first trimester GCT to predict GDM at 24-28 
weeks. We used the knee of the ROC curve to select the GCT 1h-glucose cut-off value where 
sensitivity and specificity are both optimal. Such a cut-off maximizes case-finding rates 
while minimizing false-positive rates and misclassification. Under objective 2, multivariate 
logistic regression models were performed in order to determine independent first-trimester 
predictors of GDM, using stepwise forward-backward methods: all variables collected at V1 
(Table 2) that were associated with a GDM diagnosis in univariate analyses (p≤0.10) were 
successively added to the model, based on the lowest p-value, and then removed from the 
model if not independently associated with the outcome (p>0.05) in the multivariate model. 
We calculated the area-under-the-ROC-curve (AUROC) for the post-GCT selected 1h-PG 
value and for each multivariate model. Older age was associated with increased risk of GDM 
in a non-linear fashion in our population, such that age ≥ 25 years (ADA GDM risk factor 
definition) was not associated with GDM diagnosis, but age ≥ 35 years was (CDA GDM risk 
factor definition) (Canadian Diabetes Association Clinical Practice Guidelines Expert 
Committee, 2013). This is why age ≥ 35 years, instead of 25 years, was used for multiple 
logistic regression analyses. Statistical analyses were performed using JMP version 11.0 
(SAS Institute). 
 
Results 
At V1, we recruited 1442 women who underwent a GCT. Of these, 216 women were 
excluded from the analyses (miscarriages: 101, withdrew for personal reason: 74, multiple 
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pregnancies: 15, medical abortion: 14, GCT plasma glucose ≥ 10.3 mmol/L: 11, ectopic 
pregnancy: 1). The other 1226 women were invited to V2. Of these, 46 were excluded from 
analyses (did not tolerate fasting: 12, vomited during the OGTT: 7, lost samples: 7, moved 
away from region: 7, GCT performed instead of OGTT: 6, high capillary glucose testing: 5, 
metformin therapy: 1, lost to follow-up: 1). Complete data from a total of 1180 women were 
thus analyzed.  
 
Figure 1. Course of the study. 
 
Footnotes: GCT: glucose challenge test; OGTT: oral glucose tolerance test. 
*GCT was performed instead of the OGTT. †Measured capillary glycaemia before the visit 
and were high. 
 
Characteristics of participants are provided in Table 2. Women self-reported a mean pre-
pregnancy weight of 66.0±15.1 kg. Using the measured height at first trimester, we calculated 
that the mean pre-pregnancy BMI was 24.5±5.4 kg/m2, including 35.7% of women with BMI 
≥ 25 kg/m2 and 14.8% with BMI ≥ 30 kg/m2. At V1, the mean BMI was 25.2±5.5 kg/m2. The 
V1: screening test (GCT) 
(n=1442) 
 
 
V2: diagnosis test (75g-OGTT) 
(n=1180) 
 
Miscarriages: 101 
Withdrew for personal reason: 74 
Multiple pregnancies: 15 
Abortion (voluntary or for malformation): 14 
Ectopic pregnancy: 1 
GCT ≥10.3 mmol/L: 11 
 
Do not tolerate fasting: 12 
Vomited during the OGTT: 7 
Lost samples: 7 
Moved: 7 
GCT instead of OGTT: 6* 
Capillary hyperglycemia: 5† 
Metformin therapy: 1 
Lost to follow-up: 1 
 
 
 
 
 
V2 planned for 1226 women 
 
Excluded from the 
study before the 
second visit: 216 
Excluded from the 
analysis: 46 
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correlation between the pre-gestational BMI and BMI at V1 was r = 0.986 (P<0.001). The 
mean GCT PG was 5.5±1.4 mmol/L ranging from 2.6 to 10.2 mmol/L.  
 
Table 2. Demographic and clinical variables of pregnant women (n=1180) 
 V1 
GCT visit 
V2 
OGTT visit 
Gestational age (weeks) 9.1±2.0 26.5±1.1 
Age (years) 28.2±4.4 - 
BMI (kg/m2) 25.2±5.5 27.8±5.2 
Primiparous (n, %) 568 (48.1%) - 
ADA risk factors 
  Age ≥ 25 years (n, %) 949 (80.4%) 
(78.2 – 82.7) 
- 
  Pre-pregnancy BMI ≥ 25 kg/m2 (n, %)a 417 (35.7%) 
(33.0 – 38.5) 
- 
  Non-Caucasian (n, %) 53 (4.5%) 
(3.3 – 5.7) 
- 
  Familial history of diabetes (n, %)b 135 (18.2%) 
(15.4 – 21.0) 
- 
  History of abnormal glucose tolerance (n, %)c 49 (5.7%) 
(4.1 – 7.2) 
- 
  Prior history of poor obstetrical outcomes (n,%)d 217 (24.9%) 
(22.0 – 27.8) 
- 
GCT (mmol/L) 5.5±1.4 - 
OGTT 0 min (mmol/L) - 4.2±0.4 
OGTT 60 min (mmol/L) - 7.2±1.6 
OGTT 120 min (mmol/L) - 5.9±1.4 
Results are means ± SD or n, percentage and 95% confidence interval.  
V1: visit 1; GCT: glucose challenge test; V2: visit 2; OGTT: oral glucose tolerance test; 
ADA: American Diabetes Association. adata collected in n=1165; bdata collected in n=741; 
cdata collected in n=863; ddata collected in n=872. 
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Women gained a mean of 2.6±0.3 kg/m2 of BMI (7.0±0.4kg) between V1 and V2. Mean 
OGTT PG values are shown in Table 2. According to ADA criteria, a total of 100 (8.4%) 
women were diagnosed with GDM.  
 
The ROC curve (Figure 2) indicates that the GCT 1h-PG value with optimal sensitivity and 
specificity to predict GDM is 5.6 mmol/L. This cut-off value has the following predictive 
values (95% CI) for GDM diagnosis using ADA criteria: sensitivity 82.0%, specificity 
60.8%, positive predictive value 16.2% and negative predictive value 97.3% (Table 3). In 
other words, 505 women had first trimester GCT PG ≥ 5.6 mmol/L, among which 82 were 
classified with GDM at 24-28 weeks, therefore a GCT PG > 5.6 mmol/L at first trimester 
doubles the probability to develop GDM at 24-28 weeks (16.2 vs 8.5%), while this risk is 3 
times lower (2.7 vs 8.5%) in those with PG ≤ 5.6 mmol/L. Accordingly, the LR+ of GCT is 
close to 2, which is the threshold for a good test to rule-in a condition; and its LR- is close to 
0.2, the threshold for a very good test to rule-out a disease (Sackett et al., 2000). 
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Figure 2. ROC curve of the GCT plasma glucose. 
 
Footnotes: GCT: glucose challenge test. 
 
 
 
 
 
 
5.6 mmol/L 
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Table 3. Predictive values of the GCT PG of 5.6 mmol/L for GDM diagnosis according 
to ADA criteria. 
Sensitivity (%) 82.0 (74.5 – 89.5) 
Specificity (%) 60.8 (57.9 – 63.7) 
False positive rate (%) 39.2 (36.3 – 42.1) 
False negative rate (%) 18.0 (10.5 – 25.5) 
Positive predictive value (%) 16.2 (13.0 – 19.5) 
Negative predictive value (%) 97.3 (96.1 – 98.5) 
Positive likelihood ratio 2.094 (1.86 – 2.36) 
Negative likelihood ratio 0.296 (0.19 – 0.45) 
Precision (%) 62.6 (59.9 – 65.4) 
Values are presented with 95% confidence interval. 
GCT: glucose challenge test; PG: plasma glucose; GDM: gestational diabetes mellitus; ADA: 
American Diabetes Association 
 
The first-trimester 5.6 mmol/L GCT value to discriminate women ‘at high risk of GDM’ vs. 
‘not at risk’ was significantly increased the odds of developing GDM by 7 folds (OR=7.1) 
(see Table 4). The AUROC based on the GCT 1h-PG value alone was 0.714. The best overall 
predictive model included results of the GCT and three other clinical risk factors: history of 
abnormal glucose tolerance, age ≥ 35 years and BMI ≥ 25 kg/m2. Each of the latter risk 
factors added statistically to the logistic regression model and the AUROC of the full model, 
including all 4 variables, was 0.831. However, the 1h-PG result of the first-trimester GCT 
was the single best GDM predictor (Table 4). GCT used as a continuous variable was also 
independently and significantly associated with GDM and yields results similar to those of 
the model using the 5.6 GCT cut-off (OR=1.74 per mmol/L increase, 95% CI: 1.51-2.00, 
p<0.001). 
 
 
 
 
 
 
  
 
28 
 
Table 4. Independent predictors significantly associated with GDM diagnosis according 
to ADA criteria. 
Variables OR 95% CI AUC P-value 
Model 1   0.714 <0.001 
GCT PG ≥ 5.6 mmol/L 7.08 4.29-12.3  <0.001 
Model 2   0.767 <0.001 
GCT PG ≥ 5.6 mmol/L 8.40 4.50-17.2  <0.001 
Abnormal glucose tolerance 5.16 2.52-10.4  <0.001 
Model 3   0.798 <0.001 
GCT PG ≥ 5.6 mmol/L 7.97 4.25-16.3  <0.001 
Abnormal glucose tolerance 5.14 2.47-10.5  <0.001 
Age  ≥ 35 years 3.68 1.84-7.13  <0.001 
Model 4   0.831 <0.001 
GCT PG ≥ 5.6 mmol/L 7.82 4.15-16.1  <0.001 
Abnormal glucose tolerance 5.39 2.54-11.2  <0.001 
Age  ≥ 35 years 3.60 1.78-7.09  <0.001 
BMI ≥ 25 kg/m2 2.27 1.34-3.87  0.002 
GDM: gestational diabetes mellitus; ADA: American Diabetes Association; OR: odds ratio; 
AUC: area under the curve; GCT: glucose challenge test; PG: plasma glucose. 
Multivariate logistic regression models were built using stepwise forward-backward 
methods. All variables in Table 2 associated with GDM diagnosis in univariate analyses 
(p≤0.10) were tested.  
 
Conclusion 
Different methods, using maternal clinical data and/or biomarkers, have been proposed for 
early screening of GDM during the first trimester of pregnancy. The aim of such screening 
is to protect mothers and fetuses from the short and long-term complications of GDM 
(Lacroix et al., 2013, Rasanen et al., 2013, Nanda et al., 2011, Kazandi, 2010, Punthumpol 
et al., 2008, Georgiou et al., 2008, Plasencia et al., 2011, Teede et al., 2011). Exposure to 
abnormally high concentrations of blood glucose during pregnancy can lead to abnormal fetal 
metabolic programming (Portha et al., 2011). In clinical practice, early identification of 
women at risk of developing GDM would allow the convenient detection of hyperglycemia 
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as soon as it arises during pregnancy, and thus closer follow-up, or offer preventive 
interventions. 
 
Previous studies have proposed the early identification of women at risk of GDM through a 
combination of clinical risk factors. A retrospective study (Teede et al., 2011) proposed 
considering maternal demographics and medical characteristics at first trimester including 
the ADA’s classical risk factors (see Table 2). The proposed clinical scoring system had an 
AUROC of 0.703. A clinical risk score ≥ 4 points (out of possible total 8 points) identified 
women developing GDM with a sensitivity of 61.3% and a specificity of 71.4% (Teede et 
al., 2011). This clinical risk score seems promising, should it be validated in other 
populations outside Australia, and as long as clinicians are willing to adopt a multi-factor 
scoring system. Nevertheless, clinical risk-factor scoring may be improved by additional 
biochemical predictive markers. 
 
Biochemical compounds measured early on in pregnancy as risk markers of developing 
GDM during the second trimester have been proposed as isolated predictors per se, or as part 
of a set to improve clinical risk-factor predictive scoring. One promising circulating protein 
is adiponectin. Low adiponectin levels during the first trimester of pregnancy are associated 
with increased risk of GDM in the second trimester, and this association was demonstrated 
in several cohorts including our own (Lacroix et al., 2013, Rasanen et al., 2013, Nanda et al., 
2011). Unfortunately, adiponectin is not measured in routine clinical practice. Thus, it is 
unlikely to be adopted in real life. Another proposed biomarker was sex hormone-binding 
globulin (SHBG) levels (Thadhani et al., 2003). However, adding SHBG levels to clinical 
factor predictive scores provided relatively limited additional predictive value (Nanda et al., 
2011). 
 
Hemoglobin A1c is now part of the diagnostic criteria for diabetes. It can also be 
conveniently measured in a non-fasting state. It could thus be an interesting predictive 
biomarker. In one study, no case had GDM when A1c was less than 5.2% whereas all women 
with A1c ≥ 6.1% developed GDM (Anaka et al., 2014). Another study in high-risk women 
(Garner et al., 2014) showed that, half of women with A1c between 5.7 and 6.4% had GDM, 
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whereas only 13.6% of those with A1c less than 5.7% (P=0.002) developed GDM. 
Adjustment for race and history of GDM showed that women with A1c between 5.7 and 
6.4% had five times higher estimated risk of developing GDM compared to those with A1c 
< 5.7% (OR 5.43, 95% CI 1.69-17.44) (Garner et al., 2014). Yet, because hemoglobin levels 
vary greatly during pregnancy (hemodilution, red blood cell turnover, anemia) from woman 
to woman, the use of A1c is limited.  
 
Measurement of the glycation of other proteins has also been proposed. For example, a case-
control study on 182 Finnish pregnant women showed that glycosylated fibronectin 
concentration might be considered as an early independent predictor of GDM during the first 
trimester (Rasanen et al., 2013). A threshold at 107 mg/dl had a sensitivity of 81% (95% CI 
73–89), a specificity of 90% (95% CI 84–96) and an AUROC of 0.91 (95% CI 0.87–0.96) to 
predict GDM (Rasanen et al., 2013). However, glycated fibronectin is not a biochemical 
measurement commonly available in clinical settings and its predictive value of GDM 
incidence needs to be confirmed further in a population-based study before it is considered 
for clinical application. 
 
Our results are in line with a report that 1h-glucose post-GCT at first trimester was a very 
strong predictor of risk for GDM during the second trimester with an AUROC of 0.912 
(Plasencia et al., 2011). Interestingly, -1h-PG was a better predictor than baseline glucose 
(pre-glucose load) during the GCT. One of the limitations of that study was that GDM cases 
at second trimester were diagnosed based on a two-step procedure. Thus many cases may 
have been missed since OGTT was not performed in all women. Also nor did it assess or 
propose any optimal cut-off. 
 
Our own study established that first trimester GCT is an excellent predictor of GDM in a 
large prospective population-based cohort where all women underwent a full 75g-OGTT, as 
recommended in the most recent ADA guidelines. The 1h-PG threshold of 5.6 mmol/L 
provided a sensitivity of 82.0%, specificity 60.8% and AUROC of 0.714. The AUROC 
reached 0.831 by adding three simple maternal clinical factors including history of abnormal 
glucose tolerance, age ≥ 35 years and BMI ≥25 kg/m2. This threshold is substantially lower 
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(- 2.2 mmol/L) than the 2014 value proposed by the ADA for GDM screening at the second 
trimester i.e. 7.8 mmol/L, or even the 7.2 mmol/L value of previous recommendations. Of 
note, the same screening value is recommended at the first trimester in women with risk 
factors. Our low threshold value is not surprising given the physiologic variation in glycemic 
regulation during pregnancy. Indeed, early pregnancy is usually characterized by enhanced 
insulin sensitivity which in turn decreases over the second and third trimesters (Lain and 
Catalano, 2007). 
  
Our results are in line with previous research (Plasencia et al., 2011, Nahum and Huffaker, 
1990, Bhattacharya, 2002, Yeral et al., 2013) showing a correlation between first-trimester 
GCT and early third-trimester OGTT. Furthermore, compared to other above-mentioned 
GDM screening methods used during the first trimester, GCT fulfills all WHO guideline 
criteria for screening-tests (Wilson’s Criteria) (Wilson and Jungner, 1968). GCT is also more 
feasible for health institutions than are biomarkers such as adiponectin or glycosylated 
fibronectin. Additionally, using the GCT may prove more practical than fasting PG 
measurement or OGTT for pregnant women who often preferred not to remain fasting during 
their first trimester while experiencing nausea or morning sickness.  
 
Our study showed that GCT results taken as a continuous variable are a predictor of GDM. 
However, use of a ROC curve verified optimal sensitivity and specificity with a cut-off value 
of 5.6 mmol/L. In real-life clinical practice, clinicians need cut-off values to take action. 
Here, we propose that physicians should monitor women more closely when first trimester 
GCT PG ≥ 5.6 mmol/L as well as provide advice on the adoption of healthful lifestyle habits 
that reduce the risk of GDM. Other higher-specificity thresholds could be proposed if GCT 
is used for identification of ‘very high-risk’ women to offer high intensity preventive 
interventions, or higher-sensitivity thresholds to identify women who are most unlikely to 
develop GDM in order to avoid futile GDM testing during the second trimester. 
 
To our knowledge, this is the first study of its kind specifically designed to determine GCT 
as a predictive test in a large population. We conducted the study prospectively and recruited 
a representative sample of the population of pregnant women receiving care at our tertiary 
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and quaternary care institution. GCT results were blinded until OGTT diagnosis, thus 
ensuring that study participants did not modify their lifestyle habits; consequently, our data 
were collected under real-life condition. Nevertheless, our study also has certain limitations. 
It was performed mainly in Caucasian women, due to the homogeneous population of mostly 
French/European descent in the province of Quebec and relatively low immigration rates in 
our area. Our data however can likely be generalized to other Caucasian women. Our 
hypotheses need to be now tested further in other ethnicities to determine whether the 5.6 
mmol/L cut-off value is appropriate for other ethnic groups.  
 
This prospective longitudinal cohort study in a Caucasian population showed that first-
trimester GCT predicts GDM incidence at second trimester with both high sensitivity and 
specificity. This could allow, from now on, closer follow-up and advice relating to lifestyle 
improvement early on in the first trimester of pregnancy in women found to be at risk for 
GDM. More research is clearly needed to assess whether lifestyle modification and/or 
pharmacotherapy initiated early on in pregnancy decreases complication rates of GDM or 
even avoids development of GDM all together. Thus, we propose a GCT 1h-glucose value > 
5.6 mmol/L for early identification of at-risk women and for use in future preventive-
intervention studies starting early of pregnancy.  
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DISCUSSION 
 
GDM develops with pregnancy, is asymptomatic, and has significant early and late 
complications for the mother and fetus. Pregnancy complications are prevented by treatment 
even in mild GDM (Crowther et al., 2005) while the issue of GDM for offspring has now 
gone beyond the prevention and care of perinatal morbidity to the long-term prevention of 
metabolic diseases (Metzger and Coustan, 1998, Coustan, 2010, Kim et al., 2002, Knowler 
et al., 2002, Dabelea et al., 2000, Dabelea and Pettitt, 2001). While the epidemics of obesity 
and T2DM in childhood are still not yet completely understood, prevention requires the 
careful identification of at-risk individuals through adequate screening strategies. Therefore, 
early GDM screening is crucial.  
 
Besides actual recommendations (revised above), finding the best method or test to screen 
for GDM as early as possible was the aim of many research projects around the globe. Thus, 
adiponectin was assessed by our team and others (Lacroix et al., 2013). Glycosylated 
fibronectin (Rasanen et al., 2013), combination of maternal clinical factors and biomarkers 
(Nanda et al., 2011, Georgiou et al., 2008, Teede et al., 2011), placental growth factors 
(Kazandi, 2010), and even GCT (Punthumpol et al., 2008) or 100g-OGTT (Plasencia et al., 
2011) have been also suggested. However, finding a GDM screening method which fulfills 
all WHO criteria is much more difficult.  
 
Indeed, according to WHO, screening tests aim to detect as early as possible asymptomatic 
people who probably have a given disease using a valid and reliable test with high yield at 
an affordable cost with a high acceptance for the people while follow up services are available 
(Wilson’s Criteria) (Wilson and Jungner, 1968). Simply put, 6 factors must be achieved: 1) 
early screening, 2) in asymptomatic people, 3) validity and reliability, 4) affordable costs, 5) 
acceptance, and 6) follow-up services.  
 
The method we propose, GCT at 6-13 weeks gestation for GDM screening, fulfills all above 
mentioned Wilson’s screening criteria:  
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1) Early screening. We recommend performing GCT at the 6th week after the last 
menstruation period, i.e. at earliest time for diagnosis of pregnancy. In practice, GCT 
cannot be performed earlier. 
2) Asymptomatic people. First-trimester-GCT can detect GDM as an important medical 
issue for mother and offspring, in early or latent stages of disease, whereby they can be 
managed and protected from GDM complications. 
3) Validity and reliability. GCT has been validated and used for many years for GDM 
screening at 24-28 weeks gestation; however, this current recommendation is not able to 
detect GDM as early as possible in order to prevent mother and fetus from GDM 
complications and potential fetal programming (Portha et al., 2011). The 24-28 week 
period is rather late in the evolution of a pregnancy. In our study, GCT were performed 
at 9th week, which is 17 weeks earlier than the recommended period.  
4) Affordable costs. GCT is available worldwide, and at an acceptable burden for women 
and acceptable cost for health systems, which is not the case for other tests discussed in 
our paper, such as OGTT, adiponectin, glycosylated fibronectin and others (Lacroix et 
al., 2013, Rasanen et al., 2013, Nanda et al., 2011, Georgiou et al., 2008, Teede et al., 
2011, Kazandi, 2010, Punthumpol et al., 2008, Plasencia et al., 2011). Other proposed 
methods require much more expensive equipment and are not feasible around the world 
although GCT can be realized everywhere with a reliable result. 
5) Acceptance. The absence of gastrointestinal secondary effects following GCT, i.e. 50g 
glucose load, in the whole cohort of this study, and the continuing success of the method 
implemented in our area since the creation of the Blood Sampling and Research in 
Pregnancy clinic in 2007 (Hivert et al., 2012, Allard et al., 2015) are facts implying that 
GCT in the first trimester is well accepted. Several points help to increase acceptance 
for the pregnant women and health care providers: women do not have to be fasting or 
to absorb a high load of glucose, GCT can be done anytime during the day with no 
prerequisite such as fasting. Using OGTT require fasting for several hours and 
swallowing a big (75g or 100g) load of glucose although women experience morning 
nausea and sickness during that period of pregnancy. In this study, the main reason for 
loss to follow-up was related directly to the OGTT test (19 cases) including fasting 
intolerance (12 cases) and vomiting during OGTT (7 cases). However, none of our initial 
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study population (1442 subjects) experienced nausea related to GCT during first 
trimester.  
6) Follow-up services. In industrialized countries at least, follow-up services are available. 
However, literature shows that care of GDM becomes a concern in India, China, 
Thailand, and in some African countries (Jindal et al., 2015, Chang et al., 2014, Nielsen, 
2011).  
 
Our study is the first large prospective cohort study evaluating first trimester GCT as a 
predictor of GDM diagnosis at 24-28 weeks of gestation. In addition to the screening, we 
aimed to predict during the first trimester for a GDM diagnosis during the third trimester of 
pregnancy. Different statistical models have been used to find the best predictive model for 
GDM. Our data showed that first trimester GCT as a continuous or dichotomous variable is 
an independent predictor, stronger than other usual risk factors. In addition to the first 
trimester GCT, our data demonstrated that history of abnormal glucose tolerance, age, and 
BMI can improve the predictive value of our model, and AUROC can be increased from 0.71 
(Model 1: GCT PG ≥ 5.6 mmol/L) to 0.83 (Model 4) (Table 4). 
 
We showed that a cut-off value of 5.6 mmol/L has a sensitivity and specificity of 84% and 
62%, respectively, to predict GDM. These findings are in line with several published papers 
showing a correlation between first trimester GCT results and early third trimester OGTT 
(Yeral et al., 2013, Nahum et al., 1990, Bhattacharya et al., 2002). However, these studies 
have several drawbacks: some are retrospective, they were underpowered, performed in 
heterogenic populations, or were performed in non-Caucasian (i.e. Turkish, Indian or 
Japanese, respectively) women; they were inappropriately designed, with common pitfalls 
such as: 1) only women with positive GCT performed OGTT; 2) methods used for glucose 
measurements were suboptimal, 3) it is not clear whether GCT results were blinded to 
investigators or not. In the Yeral et al. paper, two conditions are surprising: 1) women are 
Turkish or from the Middle East, i.e. at higher risk than Caucasian women; therefore, the low 
percentage of GDM (between 5.1 and 11.3%, depending on the method) is really surprising; 
this may be due to lower BMI or other risk factors. 2) the high rate of withdrawing and lost 
to follow-up (34%) is another concern. If a loss ≤ 20% does not alter the validity of 
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longitudinal studies (Fewtrell et al., 2008, Kristman et al., 2004, Touloumi et al., 2001) 34% 
is probably detrimental for a study. 
 
Our study addressed these flaws: we assessed prospectively a homogenous population of 
1180 Caucasian women, GCT results were blinded until OGTT, and a reliable method was 
used for glucose measurement. To our knowledge, this blinding of results is unique in 
literature. A distinctive aspect of our study is homogeneity: we determined a - potential - 
predictive cut-off value in a large population 95% of which was Caucasian women. This 
allows our data to be generalized to other Caucasian populations of women.  
 
Our study also showed that GCT as a continuous variable is a predictor of GDM. However, 
a ROC curve verified the optimal sensitivity and specificity, showing a cut-off value of 5.6 
mmol/L with a significant NPV (97%).  This first trimester cut-off value at least means that 
women with a GCT < 5.6 are at low risk for GDM, and should encourage healthcare providers 
to monitor more closely women with GCT ≥ 5.6 mmol/L. More research is needed before we 
suggest starting preventive management (using lifestyle or pharmacotherapy) in these women 
 
We think that our data may have several clinical implications. 
First, we believe that a lower cut-off value for GCT should be used during the first trimester 
to predict GDM at third trimester rather than the standard 24-28 week cut-off as it is 
suggested by ADA and CDA guidelines and as it was proposed by Plasencia et al. as well 
(Plasencia et al., 2011). Of note, they used a 100g-OGTT as diagnosis test, according to one 
ADA recommendation. Glucose metabolism in the first trimester is very different from that 
of the third trimester, as discussed earlier in this thesis. This should be taken into account. If 
insulin resistance is lower during the first trimester, plasma glucose cut-off values should 
logically be lower as well. Simon et al. suggested that the fasting plasma glucose cut-off 
value for GDM diagnosis during the first trimester should be as low as 4.7 mmol/L (85 mg/dl) 
(Simon et al., 2013). Plasencia et al. also showed lower glucose values during OGTT: PG 1, 
2 and 3 hours after the 100g-OGTT at 6-14 weeks was, respectively, 18, 29 and 35% lower 
than at 20-30 weeks. 
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Second, we think that using GCT for screening during the first trimester might be more 
practical than fasting PG or OGTT for pregnant women, as discussed above.  
 
Third, GCT during the first trimester can potentially increase the compliance to screening. 
This thought implies to continue to use GCT i.e. to recommend the 2-step procedure for 
screening and diagnosing GDM. We are aware that nowadays, the 1-step procedure is 
promoted, albeit carefully, by ADA, CDA and other organizations, although in practice, 
clinicians often favor the old-fashion (2-step) way. It was demonstrated that using the 
IADPSG criteria (1-step) increases the prevalence of GDM (Mahdavian et al., 2010, Langer 
et al., 2013). We think that increasing diagnosis and care is certainly a progress, with positive 
consequences to the mother and her offspring, thanks to IADPSG. However, we believe that 
if the 2-step method is used instead of the 1-step proposed by the IADPSG (IADPSG 
consensus panel, 2010), the negative impacts evoked above may vanish.  
 
Strengths and limits 
Our study has many strengths, as depicted above. It is the first of this kind: it is a large, 
double-blinded, prospective cohort study and it was performed in a very homogenous 
population. This study allowed us to calculate accurately the GDM incidence in our 
Caucasian population and to evaluate the effect of different RFs on GDM incidence. An 
additional strength was the fact that selection bias was low and the study was not biased by 
knowledge of outcome status. 
  
Our work has also limitations, including expected limitations of any prospective cohort study 
and our own specific limitations. The main expected limitations come from the sample size 
and the single-center design. A large population (more than 1000 people) was required to 
generate acceptable numbers of cases of disease (GDM) and to evaluate the predictive effect 
of RFs and early GCT tests on GDM incidence. The protocol was time consuming for 
personnel, recruitment was difficult, and more than three years (between April 2009 and June 
2012) were necessary for recruitment. Another expected bias or limitation of a prospective 
cohort study is the loss to follow up. In this study, after considering inclusion and exclusion 
criteria, 1226 pregnant women were enrolled and only 46 cases (3.7%) were excluded from 
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analysis for different reasons, including secondary effects of OGTT (see Fig 1). However, 
this does not seem to be an issue as it was shown repeatedly that loss ≤ 20% does not affect 
the validity of longitudinal studies (Fewtrell et al., 2008, Kristman et al., 2004, Touloumi et 
al., 2001).   
 
Besides, we want here to insist on three other weaknesses. First, the homogeneity of our study 
population (only Caucasian women from Quebec referred to the CHUS) is an advantage but 
also a disadvantage as it affects results generalizability: further research in other ethnicities 
is needed. Our team aims to be provided for initiating a large multicenter study, including 
centers in Toronto and Winnipeg, in order to recruit a multiethnic sample (Caribbean, Asian 
and South Asian women in Toronto, Asian and First-nation in Winnipeg). Second, 
complications of pregnancy and peripartum have not been included in this study particularly 
to compare the incidence of these complications in two groups: women (and offspring born 
to them) with GCT < 5.6 versus those with GCT ≥ 5.6 mmol/L at first trimester. Future 
investigations should explore this topic to clarify the importance of early screening and its 
effect on the incidence of GDM complications. Third, the effect of time of day on GCT cut-
off value should be investigated, given the circadian rhythm of glucose tolerance (Lee et al., 
1992, Massicotte et al., 2012). The effect of BMI of women (or weight, a more practical data 
for many clinicians) should also be assessed. We previously showed that GCT value 
increases with maternal BMI assessed at the first prenatal visit (Mahdavian et al., 2010).  
 
Finally, although we state that GCT is a validated and reliable method recommended by most 
authorities in GDM diagnosis, we must say that reproducibility is a concern for both GCT 
and OGTT. It was shown that reproducibility was 90% for normal test results and 83% for 
abnormal results when GCT was repeated on two consecutive days and that the probability 
of GCT ≤ 6.9 mmol/L to be ≥ 7.8 mmol/L was 5% (Phillipov, 1996), Time since last meal 
may induce 5% variation in positive predictive values of GCT (Sermer et al., 1994, Cetin 
and Cetin, 1997).
 
Then, we must admit that no ideal screening test for GDM has yet been 
developed. Repeating GCT another time or another day in our participants may have changed 
the 5.6 cut-off value.  
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OGTT has also limitations: test duration, time of performance (morning only after nocturnal 
fast), discomfort as well as supra-physiological glucose load unrelated to body weight
 
and 
the degree of glucose intolerance (de Nobel and Van't Laar, 1978).
 
The main issue of OGTT is 
again reproducibility. Reproducibility was 78% in a study of 64 subjects i.e. in 50 (Harlass et 
al., 1991),
 
and 1.43 mmol/L and 1.1 mmol/L differences at 1-h and 2-h, respectively, were 
found in another study (Rushforth et al., 1975).
 
When women are retested at a one-week 
interval, the variability in diagnosis varies from 10% to 24% for at first GDM women to 18% 
for non-GDM women (Langer, 2006, Catalano et al., 1993).
 
This resulted in reclassification of 
many patients. It was speculated that maternal stress contributed. Therefore our data must be 
interpreted as carefully as possible. However, our experimental conditions were very close 
to usual clinical practice, another strength of our work. Our data are realistic data, most 
probably applicable to the regular clinical setting. 
 
Future and Perspectives 
Our work was performed in a Caucasian population. For generalization of the concept, a 
multiethnic population must be assessed. This will allow us to define a cut-off value usable 
in the whole Canadian population and even world widely. This concept of general index for 
detecting women at risk of GDM is scientifically prominent; however, it is possible that huge 
ethnic differences of cut-off values will be discovered. This plausible finding will have to be 
discussed. Using various cut-offs could become a complicated procedure for physicians.    
 
The next step of our research is to determine whether this GCT cut-off during the 1st trimester 
is associated with GDM complications or not even if GDM is diagnosed and treated during 
the third trimester. If there is an association, another study should test whether treatment of 
pregnant women with GCT ≥ 5.6 mmol/L prevents development of GDM and its 
complications. This implies large prospective randomized studies in a multiethnic 
population. 
 
In conclusion, this study proposes GCT at 6-13 weeks gestation as a method to predict GDM. 
GCT fulfills all Wilson’s criteria for a screening tool. Further studies are required to 
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determine if the proposed GCT cut-off value of 5.6 mmol/L is generalizable to other 
ethnicities and operational for prevention of GDM.  
 
As glucose metabolism changes during pregnancy, the same screening and diagnostic criteria 
verified for the third trimester (24 to 28-week gestation) should be cautiously used to 
determine glucose intolerance at first trimester (6-13 week-gestation). 
 
Further investigations require to assess if predicting GDM early can prevent mother and her 
fetus from GDM and complications of GDM. These worries include long term detrimental 
consequences of fetal programming. Should our hypothesis be confirmed, screening of 
mothers and prediction of GDM will allow prevention of GDM which in turn will allow 
prevention of cardio-metabolic diseases in offspring. Our work should help to build healthier 
generations of Canadians. 
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